Koers Compugen Ltd. Deutsche Boerse AG
Aandelen
CW9
IL0010852080
Biotechnologie & Medisch Onderzoek
Geschatte realtime
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
1,705 EUR | -66,24% |
|
-9,82% | 0,00% |
Omzet 2024 * | 37,04 mln. 33,87 mln. | Omzet 2025 * | 41,12 mln. 37,6 mln. | Marktkapitalisatie | 167 mln. 153 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -4 mln. -3,66 mln. | Nettowinst (verlies) 2025 * | -1 mln. -915K | EV/omzet 2024 * | 4,52 x |
Nettoliquiditeiten 2024 * | - 0 | Nettoliquiditeiten 2025 * | - 0 | EV/omzet 2025 * | 4,07 x |
K/w-verhouding 2024 * |
-37,4
x | K/w-verhouding 2025 * |
374
x | Werknemers | 68 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 94,62% |
Recentste transcriptie over Compugen Ltd.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Anat Cohen-Dayag
CEO | Chief Executive Officer | 57 | 01-01-02 |
Alberto Sessa
DFI | Director of Finance/CFO | 61 | 01-11-22 |
Eran Ophir
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-15 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Paul Sekhri
CHM | Chairman | 66 | 02-10-17 |
Sanford Zweifach
BRD | Director/Board Member | 68 | 11-06-18 |
Gilead Halevy
BRD | Director/Board Member | 57 | 11-06-18 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+23,71% | 47,96 mld. | |
+1,95% | 42,45 mld. | |
+44,59% | 41,47 mld. | |
+28,19% | 31,6 mld. | |
+21,69% | 28,63 mld. | |
-6,35% | 28,03 mld. | |
+52,76% | 14,56 mld. | |
+49,28% | 14,14 mld. | |
+3,84% | 12,58 mld. |
- Beurs
- Aandelen
- Koers CGEN
- Koers CW9